Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective.

Jpn J Clin Oncol · 2025 · PMC12034026 · PMID 39895083

Europe PMC DOI

hedged sentence

0.0867

closest p · 1.7× alpha

0.0867

boldest claim

The sentences

a favorable trendP = .0867so close (0.05 < p ≤ 0.1)

In addition, a favorable trend of overall survival (hazard ratio 0.80; 95% CI, 0.57–1.11; P = .0867) and a significantly better objective response rate (TACE plus pembrolizumab + Len, 71.3%; TACE + placebo, 49.8%; P < .0001) were also reported for TACE plus pembrolizumab + Len.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.